Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting [Yahoo! Finance]
Zymeworks Inc. (ZYME)
Last zymeworks inc. earnings: 3/2 04:15 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.zymeworks.com/overview
Company Research
Source: Yahoo! Finance
diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five presentations including new data from its preclinical development-stage programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, California April 5-10, 2024. “Our team is looking forward to share new data from our strong portfolio of multispecific antibody therapeutics and antibody-drug conjugates including ZW191, an anticipated 2024 IND candidate,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. “These data provide important new insights highlighting the potential of our candidates to represent major advances in the treatment of cancer while also demonstrating the potential to develop a new generation of novel antibody-drug conjugates and multispecific antibody therapeutics.” Presentation Highlights ZW191 - a FRa-targeting antibody-drug conjugate with strong preclinical
Show less
Read more
Impact Snapshot
Event Time:
ZYME
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZYME alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZYME alerts
High impacting Zymeworks Inc. news events
Weekly update
A roundup of the hottest topics
ZYME
News
- Zymeworks Inc. (NYSE: ZYME) had its price target lowered by analysts at Citigroup Inc. from $17.00 to $16.00. They now have a "buy" rating on the stock.MarketBeat
- Zymeworks Inc. (NYSE: ZYME) had its price target lowered by analysts at Wells Fargo & Company from $14.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Lost Money on Zymeworks Inc.(ZYME)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire
- Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ZYME
Earnings
- 5/2/24 - Miss
ZYME
Sec Filings
- 5/3/24 - Form 8-K
- 5/3/24 - Form 424B5
- 5/3/24 - Form 424B5
- ZYME's page on the SEC website